Your browser doesn't support javascript.
loading
Efficacy and safety of twice-daily tramadol hydrochloride bilayer sustained-release tablets with an immediate release component for postherpetic neuralgia: Results of a Phase III, randomized, double-blind, placebo-controlled, treatment-withdrawal study.
Kawai, Shinichi; Hasegawa, Jun; Ito, Hideki; Fukuuchi, Yasuo; Nakano, Hideshi; Ohtani, Hideaki; Sasaki, Kazutaka; Adachi, Takeshi.
Affiliation
  • Kawai S; Department of Inflammation & Pain Control Research, Toho University School of Medicine, Tokyo, Japan.
  • Hasegawa J; Sakurashinmachi Pain Clinic, Tokyo, Japan.
  • Ito H; Tachikawa Dermatology Clinic, Tokyo, Japan.
  • Fukuuchi Y; Fukuuchi Pain Clinic, Tokyo, Japan.
  • Nakano H; Department of Clinical Development, Nippon Zoki Pharmaceutical Co., Ltd., Osaka, Japan.
  • Ohtani H; Department of Clinical Development, Nippon Zoki Pharmaceutical Co., Ltd., Osaka, Japan.
  • Sasaki K; Department of Clinical Development, Nippon Zoki Pharmaceutical Co., Ltd., Osaka, Japan.
  • Adachi T; Department of Clinical Development, Nippon Zoki Pharmaceutical Co., Ltd., Osaka, Japan.
Pain Pract ; 23(3): 277-289, 2023 03.
Article in En | MEDLINE | ID: mdl-36478501
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Tramadol / Neuralgia, Postherpetic Type of study: Clinical_trials Limits: Humans Language: En Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Tramadol / Neuralgia, Postherpetic Type of study: Clinical_trials Limits: Humans Language: En Year: 2023 Type: Article